CA-CROWN-BIOSCIENCE
Crown Bioscience, a JSR Life Sciences company and leading contract research organization (CRO) in preclinical and translational drug development services, today announced that it has completed the expansion and renovation of its Crown Bioscience United Kingdom facility. The additional laboratory and office space will increase capacity and expand the company’s current in vivo offering by 30 percent and provide dedicated space for a newly acquired high frequency ultrasound unit – a specialized high-resolution imaging device designed to increase the utility of two- and three-dimensional imaging without the need for cell line-tagging, coupled with high precision guided inoculation/dosing of orthotopic and metastatic models.
“This expansion is a critical step in our ability to provide additional imaging modalities to better visualize and understand tumor progression and response to potential therapies,” said Yinfei Yin, PhD, General Manager at Crown Bioscience UK. “This additional imaging platform allows us to perform cutting-edge preclinical studies, offering our customers advanced insights on potential drug candidates before they enter clinical trials.”
The Company’s UK site leverages more than 15 years of experience in in vivo optical imaging, including bioluminescence, fluorescence and microCT modalities. Specifically, the addition of high frequency ultrasound will enable better longitudinal evaluation of tumor growth and earlier, more detailed analytics on the tumor microenvironment.
“This site expansion is driven by increased customer demand for access to Crown Bioscience’s in vivo services from the UK and mainland Europe, and allows us to build upon our innovative foundation to develop additional industry-leading technologies,” said Armin Spura, PhD, Chief Executive Officer of Crown Bioscience. “Following our recent acquisition of OcellO B.V. and launch of our 3D Ex Vivo Patient Tissue Platform , this milestone enables Crown Bioscience to continue to use the power of partnership to unlock breakthroughs in drug discovery and, ultimately, to provide patients with better treatment options.”
Crown Bioscience UK serves customers advancing preclinical and clinical oncology and immuno-oncology studies. The site offers a comprehensive suite of in vivo models, including PDX, CDX and syngeneic portfolios incorporating orthotopic, metastatic, and systemic variations, as well as in vitro and ex vivo services, such as cell viability, invasion/migration assays, immunoassays, 3D-TGA and combination studies/analysis.
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) providing preclinical and translational platforms to advance oncology, immuno-oncology, and immune-mediated inflammatory diseases. The company is the only preclinical CRO to provide tumor organoid services utilizing HUB technology and has the world’s largest commercially available PDX collection. Crown Bioscience helps deliver superior drug candidates to ensure that patients get the right treatment at the right time. Founded in 2006, Crown Bioscience has nine facilities in the US, Europe and Asia. Find out more: www.crownbio.com .
###
View source version on businesswire.com: https://www.businesswire.com/news/home/20211208005004/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Interactive Brokers Unveils Investment Themes Tool to Turn Market Trends into Smarter Trades16.7.2025 16:00:00 CEST | Press release
New discovery feature helps investors quickly explore market trends, compare companies, and find opportunities Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, announced the release of Investment Themes, an intuitive discovery tool powered by Reflexivity that investors can use to move from market trends to actionable trade ideas more quickly and confidently. Available across IBKR’s powerful trading platforms, Investment Themes simplifies the research process by connecting companies, products, competitors, and regions across the entire S&P 1500 universe. The underlying thematic intelligence was developed by Reflexivity, leveraging its proprietary knowledge graph to map the real-world relationships between companies and their business drivers. Investment Themes turns complex market data into clear, interactive insights. Investors can start with a topic like “Generative AI” or “Nuclear Energy” and instantly view the public companies tied to that theme, without ne
Qualcomm Schedules Third Quarter Fiscal 2025 Earnings Release and Conference Call16.7.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced that it will publish the Company’s financial results for its third quarter of fiscal 2025 on Wednesday, July 30, 2025, after the close of the market on the Company’s Investor Relations website, at https://investor.qualcomm.com/financial-information. The earnings release will also be furnished to the Securities and Exchange Commission (SEC) on a Form 8-K, which will be available on the SEC website at http://www.sec.gov. Qualcomm will host a conference call to discuss its third quarter fiscal 2025 results which will be broadcast live on July 30, 2025, beginning at 1:45 p.m. Pacific Time (PT) at https://investor.qualcomm.com/news-events/investor-events/default.aspx. An audio replay will be available at https://investor.qualcomm.com/news-events/investor-events/default.aspx and via telephone following the live call for 30 days thereafter. To listen to the replay via telephone, U.S. callers may dial (877) 660-6853 and international callers
Quectel Unveils High-Performance KCMA32S Zigbee & BLE Module for Smart Lighting, Building and Home Networks16.7.2025 15:00:00 CEST | Press release
Quectel Wireless Solutions, a global IoT solutions provider, has announced the launch of its latest high-performance MCU Zigbee and BLE module, the KCMA32S. This innovative module is designed to meet the growing demands of IoT applications, featuring advanced connectivity options and a compact form factor. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716499223/en/ Quectel unveils high-performance KCMA32S Zigbee & BLE module for smart lighting, building and home networks Powered by Silicon Labs’ ultra-low-power EFR32MG21 wireless SoC, the KCMA32S module supports Zigbee 3.0 and BLE 5.3, enabling multi-protocol coexistence for enhanced communication capabilities. It is powered by an ARM Cortex-M33 processor with a frequency of up to 80 MHz, ensuring efficient performance for a wide range of applications. The module offers flexible memory configurations to suit various applications, with options of 64 KB RAM and 768 KB flas
Belgravia Hartford Announces USD$5M Convertible Secured Debenture with Round13 DAF & Closing of C$4M Private Placement16.7.2025 14:57:00 CEST | Press release
Total Proceeds in Excess of C$10.86M for Bitcoin Purchases BELGRAVIA HARTFORD CAPITAL INC. (CSE:BLGV)(OTC:BLGVF)(FRA:ECA) ("Company" or “Belgravia”) is pleased to announce that: it has entered into a binding agreement with Round13 Digital Asset Fund (“Round13 DAF”) for a secured convertible debenture for a one-time principal amount investment of USD$5,000,000 (the “Debenture”) convertible into common shares at C$0.71, being a 40% premium to the volume-weighted average trading price (the “VWAP”) for the seven consecutive days immediately preceding the date of this announcement; and as a result of this above-market Debenture, Belgravia has elected to voluntarily reduce its non-brokered private placement to close on 16,091,822units (the “Units”) at a price of C$0.25 per Unit for aggregate gross proceeds of C$4,022,955.55(the “Offering”) to the Company. New USD$5 Million Round13 DAF Debenture Convertible at C$0.71 The principal amount and interest of the Debenture is convertible into commo
SLB Completes Acquisition of ChampionX16.7.2025 14:50:00 CEST | Press release
Enhanced portfolio drives innovation in production and reservoir recovery, expands SLB’s presence in high-growth vertical, and accelerates digital adoption SLB (NYSE: SLB) announced today that it has closed its previously announced acquisition of ChampionX Corporation. Under the terms of the agreement, ChampionX shareholders received 0.735 shares of SLB common stock in exchange for each ChampionX share. With the closing of the transaction, former ChampionX shareholders now own approximately 9% of SLB’s outstanding shares of common stock. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715857114/en/ The integration of ChampionX production chemicals and its complementary artificial lift, digital, and emissions technologies enhances the SLB portfolio, helping to drive performance and extend asset life along the production lifecycle. This strategic acquisition strengthens SLB's leadership in the production and recovery space.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom